290 related articles for article (PubMed ID: 24957789)
1. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
Kim JH; Park J
Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
[TBL] [Abstract][Full Text] [Related]
2. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
3. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.
Zhang Q; Zhao Z; Ma Y; Wang H; Ma J; He X; Zhang D
Urol Oncol; 2014 Aug; 32(6):798-805. PubMed ID: 24968947
[TBL] [Abstract][Full Text] [Related]
4. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
6. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
7. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
[TBL] [Abstract][Full Text] [Related]
9. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
10. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.
Matsumoto K; Irie A; Satoh T; Ishii J; Iwabuchi K; Iwamura M; Egawa S; Baba S
Urology; 2007 Sep; 70(3):602-7. PubMed ID: 17688917
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
[TBL] [Abstract][Full Text] [Related]
12. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
14. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Yun SJ; Jo SW; Ha YS; Lee OJ; Kim WT; Kim YJ; Lee SC; Kim WJ
Urol Oncol; 2012; 30(6):893-9. PubMed ID: 21396842
[TBL] [Abstract][Full Text] [Related]
15. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
18. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
19. High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer.
Zhang Q; Hao C; Cheng G; Wang L; Wang X; Li C; Qiu J; Ding K
Int J Clin Exp Pathol; 2015; 8(9):11510-6. PubMed ID: 26617883
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma.
Shah CH; Viktorsson K; Kanter L; Sherif A; Asmundsson J; Rosenblatt R; Lewensohn R; Ullén A
Urol Oncol; 2014 Nov; 32(8):1215-24. PubMed ID: 24880461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
